Comment on Dor

Dor is going to get stopped by the FDA panel -- I don't see it having much of a chance of getting approval for a wide variety of reasons. Their treatment is totally different in scope, technoogy and improtance to patients than Provenge and comparisons are valid only if you look at both and say their applications are being supported by weak statistical data.

Not to mention the panel comes under the auspices of CDER (the Center for Drug Evaluatin and Research) not the CBER group (Center for Biologics Evaluation and Research), and CDER are statistical freaks. I am not as familiar with Dor as I am with other comapnies but I would stay away.